Among the agents able to prevent aggregation of the mutant ataxin-1 and the consequent neurotoxicity, bromocriptine methylate (BRC), a potent DRD2 agonist approved for the treatment of Parkinson’s disease, showed promising results in ALS preclinical studies (Tanaka et al. 2011; Hearst et al. 2010). The gene discussed is DRD2; the disease is Parkinson disease.